methylprednisolone has been researched along with Chronic Progressive Multiple Sclerosis in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 14 (48.28) | 29.6817 |
| 2010's | 12 (41.38) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Espiritu, AI; Jalipa, FGU; Pasco, PMD | 1 |
| Bielekova, B; Börnsen, L; Komori, M; Ratzer, R; Romme Christensen, J; Sellebjerg, F; von Essen, MR | 1 |
| Finck, TLK; Fischer, HJ; Lühder, F; Pellkofer, HL; Reichardt, HM | 1 |
| Bisaga, GN; Karpov, MI; Mikhal'tsova, EN; Odinak, MM; Sokolov, AA | 1 |
| Ammitzbøll, C; Andersen, B; Börnsen, L; Dyrby, TB; Garde, E; Hyldstrup, L; Iversen, P; Lyksborg, M; Madsen, CG; Ratzer, R; Romme Christensen, J; Sellebjerg, F; Siebner, HR; Sørensen, PS | 1 |
| Balkuv, E; Basaran, R; Duruyen, S; Isbilen, B; Isik, N; Kocer, A; Varoglu, AO | 1 |
| Baschet, L; Brochet, B; Castelnovo, G; Clavelou, P; Cohen, M; Collongues, N; de Sèze, J; Debouverie, M; Deloire, MS; Labauge, P; Lebrun, C; Loock, T; Ouallet, JC; Perez, P; Pittion, S; Ruet, A; Vermersch, P; Zéphir, H | 1 |
| Araújo, EA; Freitas, MR | 1 |
| Aristimuño, C; de Andrés, C; Fernández-Cruz, E; Giménez-Roldán, S; Martínez-Ginés, L; Navarro, J; Sánchez-Ramón, S | 1 |
| Araujo, EA; Araújo, MA; Freitas, MR; Santos, AA | 1 |
| Abellán, I; Belenguer, A; Boscá, I; Casanova, B; Coret, F; Fernández, P; Magraner, MJ; Mallada, J; Montalbán, X; Pascual, AM; Sanz, MA; Sempere, AP; Téllez, N | 1 |
| Dijkstra, CD; Polman, CH; Tilders, FJ; Uitdehaag, BM; van Winsen, LM | 1 |
| Börnsen, L; Khademi, M; Olsson, T; Sellebjerg, F; Sørensen, PS | 1 |
| Bisaga, GN; Boĭko, AN; Mel'nik, IuB; Odinak, MM; Popova, NF | 1 |
| Hassinger, S; Lindquist, JA; Lindquist, S; Sailer, M | 1 |
| Andrews, M; Bergsland, N; Carl, E; Cherneva, M; Dwyer, MG; Heininen-Brown, M; Hojnacki, D; Hussein, S; Kennedy, C; Weinstock-Guttman, B; Willis, L; Zivadinov, R | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T | 1 |
| Boggild, M; Ford, H | 1 |
| Edan, G | 1 |
| Chatel, M; De Seze, J; Lacour, A; Lebrun, C; Masmoudi, K; Revenco, E; Rumbach, L; Verier, A; Vermersch, P; Vidry, E | 1 |
| Bourg, V; Chanalet, S; Chatel, M; Delmont, E; Lebrun, C; Soriani, MH | 1 |
| Pirko, I; Rodriguez, M | 1 |
| Brandt, T; Gross, A; Hohlfeld, R; Jahn, K; Strupp, M; Zingler, VC | 1 |
| Bouillaguet, S; Cabaret, M; de Seze, J; Dubois, G; Dujardin, K; Ferriby, D; Stojkovic, T; Vermersch, P; Zéphir, H | 1 |
| Bühler, R; Humm, AM; Magistris, MR; Rösler, KM; Z'Graggen, WJ | 1 |
| Armstrong, MA; Boylan, MT; Crockard, AD; Hawkins, SA; McDonnell, GV | 1 |
| Chatterjee, VK; Coles, AJ; Compston, A; Coraddu, F; Greer, S; Hale, G; Smith, S; Taylor, C; Waldmann, H; Weetman, A; Wing, M | 1 |
| Antonello, RM; Cazzato, G; Moretti, R; Torre, P; Zorzon, M | 1 |
| Lublin, FD | 1 |
5 review(s) available for methylprednisolone and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Re-examining the effects of high-dose intravenous methylprednisolone for secondary progressive multiple sclerosis.
Topics: Administration, Intravenous; Adult; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Randomized Controlled Trials as Topic; Recurrence | 2021 |
[2012: Update on diagnosis and treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Brain; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Immunosuppressive Agents; Infusions, Intravenous; Interferon-beta; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Plasmapheresis; Propylene Glycols; Pulse Therapy, Drug; Sphingosine; Spinal Cord | 2012 |
Multiple sclerosis.
Topics: Adrenocorticotropic Hormone; Drug Administration Routes; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Methylprednisolone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
[Aggressive multiple sclerosis. Definition and specific therapeutic indication].
Topics: Adjuvants, Immunologic; Adult; Analgesics; Anti-Inflammatory Agents; Clinical Trials as Topic; Diagnosis, Differential; Female; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Monitoring, Physiologic; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Patient Selection; Placebos; Risk Assessment; Risk Factors; Time Factors | 2004 |
Therapeutic approaches to secondary progressive multiple sclerosis.
Topics: Anti-Inflammatory Agents; Azathioprine; Bone Marrow Transplantation; Cladribine; Clinical Trials as Topic; Cyclosporine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Methotrexate; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Chronic Progressive | 2002 |
10 trial(s) available for methylprednisolone and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.
Topics: Adult; Anti-Inflammatory Agents; Axons; Biomarkers; Female; Follow-Up Studies; Humans; Immunologic Factors; Inflammation; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Natalizumab; Neurofilament Proteins; Outcome Assessment, Health Care | 2019 |
Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Biomarkers; Bone Density; Denmark; Diffusion Tensor Imaging; Disease Progression; Evoked Potentials, Motor; Female; Glucocorticoids; Humans; Inflammation Mediators; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neurologic Examination; Osteopontin; Predictive Value of Tests; Pulse Therapy, Drug; Recovery of Function; Recurrence; Time Factors; Treatment Outcome; Young Adult | 2016 |
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Cyclophosphamide; Disabled Persons; Disease Progression; Double-Blind Method; Female; France; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Proportional Hazards Models; Severity of Illness Index; Young Adult | 2017 |
Expansion of regulatory CD8+ T-lymphocytes and fall of activated CD8+ T-lymphocytes after i.v. methyl-prednisolone for multiple sclerosis relapse.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Glucocorticoids; Humans; Interleukin-2 Receptor alpha Subunit; Linear Models; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; T-Lymphocytes, Regulatory; Young Adult | 2008 |
Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis.
Topics: Adult; Biomarkers; Dexamethasone; Disability Evaluation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance; Female; Glucocorticoids; Humans; Inflammation Mediators; Leukocytes, Mononuclear; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2010 |
[Possibilities of treatment of multiple sclerosis exacerbations without corticosteroids: a role of metabolic and antioxidant therapy].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antioxidants; Autoantibodies; Cognition; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Lipid Peroxidation; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myelin Sheath; Niacinamide; Pentoxifylline; Succinates; Vitamin B Complex; Young Adult | 2011 |
Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Brain; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunologic Factors; Infusions, Intravenous; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; New York; Predictive Value of Tests; Prospective Studies; Pulse Therapy, Drug; Single-Blind Method; Time Factors; Treatment Outcome | 2012 |
[The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients].
Topics: Adult; Aged; Analgesics; Disease Progression; Drug Combinations; Female; Humans; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Prognosis; Recovery of Function; Secondary Prevention; Treatment Outcome | 2005 |
One-year cyclophosphamide treatment combined with methylprednisolone improves cognitive dysfunction in progressive forms of multiple sclerosis.
Topics: Adult; Anti-Inflammatory Agents; Cognition; Cognition Disorders; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Prospective Studies; Treatment Outcome | 2005 |
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antirheumatic Agents; B-Lymphocyte Subsets; CD4 Antigens; CD52 Antigen; Drug Administration Schedule; Female; Follow-Up Studies; Glycoproteins; Graves Disease; Humans; Lymphocyte Activation; Male; Methylprednisolone; Multiple Sclerosis, Chronic Progressive; Pulse Therapy, Drug; Receptors, Tumor Necrosis Factor; T-Lymphocyte Subsets; Th1 Cells; Thyroiditis, Autoimmune | 1999 |
14 other study(ies) available for methylprednisolone and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Glucocorticoid Therapy of Multiple Sclerosis Patients Induces Anti-inflammatory Polarization and Increased Chemotaxis of Monocytes.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Chemokine CCL2; Chemotaxis, Leukocyte; Female; Humans; Male; Methylprednisolone; Middle Aged; Monocytes; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Pulse Therapy, Drug; Receptors, CCR2; Receptors, Cell Surface; Receptors, Glucocorticoid; Young Adult | 2019 |
[Effect of therapeutic apheresis on the lymphocyte sensitivity to corticosteroids in patients with secondary progressive multiple sclerosis].
Topics: Blood Component Removal; Female; Follow-Up Studies; Glucocorticoids; Humans; Lymphocytes; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Time Factors; Treatment Outcome | 2013 |
The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis.
Topics: Adult; Anti-Inflammatory Agents; Disability Evaluation; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Protein C; Thrombomodulin | 2016 |
Benefit with methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis: study of 11 cases in 11 years.
Topics: Adult; Age Distribution; Anti-Inflammatory Agents; Dosage Forms; Female; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Sex Distribution; Young Adult | 2008 |
Progressive primary form of multiple sclerosis: clinical and radiological improvement with methylprednisolone in continuous pulsetherapy in one case for 16 years.
Topics: Adult; Anti-Inflammatory Agents; Female; Humans; Magnetic Resonance Imaging; Methylprednisolone; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Pulse Therapy, Drug | 2009 |
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Child; Cohort Studies; Female; Humans; Interferon Type I; Leukemia, Myeloid, Acute; Male; Mediterranean Region; Methylprednisolone; Middle Aged; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recombinant Proteins; Risk Assessment; Young Adult | 2009 |
Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.
Topics: Adult; Cross-Sectional Studies; Demyelinating Diseases; Diffusion Magnetic Resonance Imaging; Disability Evaluation; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Osteopontin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
Topics: Adult; Brain-Derived Neurotrophic Factor; Case-Control Studies; Cell Separation; Cells, Cultured; Ciliary Neurotrophic Factor; Drug Therapy, Combination; Female; Flow Cytometry; Glucocorticoids; Humans; Immunologic Factors; Inflammation Mediators; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Leukocytes, Mononuclear; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Nerve Growth Factors; Nitric Oxide Synthase Type II; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2011 |
Acute aphasia in multiple sclerosis: A multicenter study of 22 patients.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Aphasia; Azathioprine; Brain; Cohort Studies; Comorbidity; Disease Progression; Female; France; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Prevalence; Recovery of Function | 2004 |
[Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response].
Topics: Adjuvants, Immunologic; Adult; Azathioprine; Brain; Cyclophosphamide; Demography; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Prospective Studies; Pulse Therapy, Drug; Recurrence; Retrospective Studies | 2004 |
Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial.
Topics: Adult; Controlled Clinical Trials as Topic; Female; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive | 2004 |
Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone.
Topics: Adult; Dose-Response Relationship, Drug; Evoked Potentials, Motor; Female; Humans; Infusions, Intravenous; Isometric Contraction; Male; Methylprednisolone; Middle Aged; Motor Neuron Disease; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Neural Conduction; Optic Neuritis; Pyramidal Tracts; Treatment Outcome | 2006 |
CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone.
Topics: Antigens, CD; B-Lymphocytes; B7-1 Antigen; B7-2 Antigen; Case-Control Studies; Female; Humans; Interferon-gamma; Male; Membrane Glycoproteins; Methylprednisolone; Monocytes; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting | 1999 |
Recurrent atrial fibrillation associated with pulse administration of high doses of methylprednysolone: a possible prophylactic treatment.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Electrocardiography; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Propafenone; Pulse Therapy, Drug; Treatment Outcome | 2000 |